Trials / Terminated
TerminatedNCT02078089
Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain
A Phase Ib Study of Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Costantine Albany · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single arm, Phase Ib dose escalation study of Oxcarbazepine with morphine in patients with refractory cancer pain. The primary endpoint is to evaluate the safety and toxicity of the combination of Oxcarbazepine plus morphine. The secondary endpoints are improving pain control, reduce morphine use and improve the quality of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Morphine | Morphine will be given to patients as part of their standard care |
| DRUG | Oxcarbazepine | Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge. |
Timeline
- Start date
- 2014-03-06
- Primary completion
- 2014-12-11
- Completion
- 2014-12-11
- First posted
- 2014-03-05
- Last updated
- 2017-01-31
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02078089. Inclusion in this directory is not an endorsement.